Mednet Logo

How do you choose bridging therapy prior to CAR-T leukapheresis?

Are there agents (eg. bendamustine) or modalities to avoid? Does washout times prior to collection vary between modalities?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on

There is a lack of uniform clarity around terminology here. To avoid confusion, I prefer using "debulking" for treatment that is administered prior to T-cell apheresis, and "bridging" for treatment administered after apheresis to bridge the patient during manufacture to maintain disease control prio...

Join for free or sign in to see the full answer